Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential.
chronic myeloid leukemia
glucose
glutamine
low oxygen
minimal residual disease
stem cell niche
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Aug 2021
30 Aug 2021
Historique:
received:
15
07
2021
revised:
22
08
2021
accepted:
27
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
This study was directed to characterize the role of glutamine in the modulation of the response of chronic myeloid leukemia (CML) cells to low oxygen, a main condition of hematopoietic stem cell niches of bone marrow. Cells were incubated in atmosphere at 0.2% oxygen in the absence or the presence of glutamine. The absence of glutamine markedly delayed glucose consumption, which had previously been shown to drive the suppression of BCR/Abl oncoprotein (but not of the fusion oncogene
Identifiants
pubmed: 34503182
pii: cancers13174372
doi: 10.3390/cancers13174372
pmc: PMC8430815
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG23607
Organisme : Regione Toscana
ID : stemCMLcure
Organisme : Istituto Toscano Tumori
ID : ITT2016PDS
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG13466
Références
Oncotarget. 2016 Dec 20;7(51):84810-84825
pubmed: 27852045
Int J Cell Cloning. 1983 Jun;1(2):105-17
pubmed: 6321612
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
Nature. 1973 Jun 1;243(5405):290-3
pubmed: 4126434
Cell Cycle. 2012 Oct 1;11(19):3679-90
pubmed: 22935705
Nat Med. 2017 Oct;23(10):1234-1240
pubmed: 28920959
Genes Dev. 2010 Dec 15;24(24):2784-99
pubmed: 21106670
Blood. 1975 Mar;45(3):321-34
pubmed: 163658
Dev Cell. 2016 Mar 7;36(5):540-9
pubmed: 26954548
Cancer Res. 2013 Jul 15;73(14):4429-38
pubmed: 23687346
Cell Stem Cell. 2011 Oct 4;9(4):298-310
pubmed: 21982230
Cell Stem Cell. 2013 Mar 7;12(3):329-41
pubmed: 23333149
Cancer Metab. 2019 Dec 27;7:11
pubmed: 31890203
Oncogenesis. 2016 Jan 25;5:e190
pubmed: 26807645
Cell Stem Cell. 2010 Aug 6;7(2):150-61
pubmed: 20682444
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50
pubmed: 18032601
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):710-723
pubmed: 30093283
Cell Cycle. 2014;13(20):3169-75
pubmed: 25485495
Blood. 1993 Oct 1;82(7):2031-7
pubmed: 8104535
Haematologica. 2011 Feb;96(2):204-12
pubmed: 21071498
PLoS Comput Biol. 2017 Sep 28;13(9):e1005758
pubmed: 28957320
FASEB J. 2002 May;16(7):733-5
pubmed: 11923217
Oncogene. 2005 May 5;24(20):3257-67
pubmed: 15735728
Stem Cells Int. 2017;2017:4979474
pubmed: 29118813
Methods Mol Biol. 2016;1465:73-85
pubmed: 27581140
J Clin Invest. 2008 Dec;118(12):3930-42
pubmed: 19033663
Curr Pharm Des. 2013;19(30):5374-83
pubmed: 23394087
Mol Syst Biol. 2013 Dec 03;9:712
pubmed: 24301801
Cell Stem Cell. 2010 Sep 3;7(3):380-90
pubmed: 20804973
Stem Cell Reports. 2018 Oct 9;11(4):929-943
pubmed: 30245209
J Med Chem. 2019 Feb 14;62(3):1096-1115
pubmed: 30148361
Leukemia. 2000 Apr;14(4):735-9
pubmed: 10764163
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5431-6
pubmed: 17374716
Hypoxia (Auckl). 2014 Jan 21;2:1-10
pubmed: 27774462
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14878-83
pubmed: 19706488
Future Med Chem. 2013 Sep;5(14):1685-700
pubmed: 24047273
J Nucl Med. 2018 Sep;59(9):1340-1349
pubmed: 30042161
Blood. 2017 Aug 3;130(5):655-665
pubmed: 28576876
Tumour Biol. 2016 May;37(5):6027-34
pubmed: 26596840
Cell Metab. 2014 Jan 7;19(1):37-48
pubmed: 24332967
Stem Cells. 2007 May;25(5):1119-25
pubmed: 17255519
Blood. 2002 Jan 1;99(1):319-25
pubmed: 11756187
Am J Pathol. 2012 Feb;180(2):494-504
pubmed: 22115707
Exp Mol Med. 2020 Sep;52(9):1496-1516
pubmed: 32943735
Neoplasia. 2020 Jan;22(1):22-32
pubmed: 31765939
Clin Exp Metastasis. 2011 Dec;28(8):865-75
pubmed: 21842413
Leukemia. 2006 Jul;20(7):1291-3
pubmed: 16710305